PDA

PDA, or penta-deca-arginate, is a stabilized synthetic peptide developed as a structural analog within the same peptide family associated with tissue repair signaling. The arginate modification is designed to enhance the peptide's stability and receptor engagement compared to earlier-generation compounds in this class. Like other peptides in this family, PDA is studied for its interaction with growth factor and angiogenesis-related pathways that support the body's natural tissue repair and remodeling processes. EdgeRx offers PDA through a clinician-supervised protocol, prescribed by licensed physicians for eligible patients seeking a next-generation option within a tissue repair-focused recovery plan.